U.S., March 25 -- ClinicalTrials.gov registry received information related to the study (NCT06891716) titled '[18F]ACI-19626 PET in TDP-43 Proteinopathies' on March 18.
Brief Summary: The goal of this clinical trial is to test whether we can reliably and safely measure the accumulation of pathological protein TDP-43 [involved in rare forms of dementia such as frontotemporal dementia (FTD) and in amyotrophic lateral sclerosis (ALS)] using a new positron emission tomography (PET) tracer called [18F]ACI-19626. Both healthy people and people with (suspected) TDP-43 accumulation will participate to this trial.
The main questions it aims to answer are:
* whether [18F]ACI-19626 is safe and well tolerated when injected into participants
* wheth...